Obstructive Sleep Apnea Syndrome (OSAS) is a pervasive disorder affecting 2%-4% of adults worldwide.
While Continuous Positive Airway Pressure (CPAP) devices are the established therapy for moderate and severe cases, their tolerability remains an issue, with only 50%-70% of patients adapting to CPAP therapy. Enter myofunctional therapy, an increasingly viable alternative, especially with the advent of Functional Growth Guidance (FGB) devices.
CPAP therapy involves the continuous pumping of air into the respiratory system through a mask, which can be uncomfortable and hinder compliance.
Myofunctional therapy, in conjunction with FGB devices, provides a compelling alternative. By focusing on strengthening the oropharyngeal musculature, this approach targets the root cause of upper airway collapse, a hallmark of OSAS. Notably, this is achieved without the encumbrance of a mask, significantly enhancing patient adherence.
Over the last few years, myofunctional therapy, complemented by FGB devices, has gained recognition for its efficacy in OSAS patients. Beyond its success in improving physiological markers, the therapy has demonstrated positive outcomes in terms of patient compliance, addressing a critical concern associated with traditional CPAP methods.
As FGB devices continue to evolve, they stand as a transformative force in sleep apnea treatment, providing a more comfortable and effective solution for patients.